Lead Product(s): Belimumab
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Large molecule
Deal Size: $231.0 million Upfront Cash: Undisclosed
Deal Type: Agreement May 21, 2020
Under the terms of the agreement, Samsung Biologics will provide GSK with additional capacity for large-scale biopharmaceutical product manufacturing. This capacity will be flexible depending on GSK’s future needs and will supplement GSK’s existing manufacturing network.